Albumedix Is Now Part Of Sartorius

Albumedix Is Now Part of Sartorius

Empowering Excellence in the Hands of Our Partners

As a science-driven company and recognized leader of best-in-class albumin-enabled solutions, Albumedix enables the development and commercialisation of advanced therapies and next-generation biopharmaceuticals to the benefit of people worldwide.

Albumedix empowers excellence in your applications; combining high-quality, safe & consistent recombinant human albumin products, bespoke service packages tailor-made to enable your success, and innovative technologies.

Sartorius Completes Acquisition of Albumedix

Read Press Release

Explore Albumedix´ Solutions

Recombumin® Recombinant Human Albumin

Find high-quality animal and human-origin-free recombinant human albumins in the Recombumin® product portfolio.

Established in the UK in 1984, Albumedix, now a part of Sartorius, has supported its life science partners to deliver hundreds of millions of doses of clinical and marketed therapeutics, globally. The Recombumin® portfolio of recombinant human albumins includes the world’s only USP-NF compliant recombinant human albumin.

Recombumin® recombinant human albumin products are produced in a proprietary yeast strain (Saccharomyces cerevisiae) to ICHQ7 cGMP standards, formulated in the United Kingdom, and distributed worldwide to support our customers.

Blog

How Recombinant Albumin Supports the World’s First Chikungunya Vaccine

Ensuring stability during storage and transport was a critical task for Sartorius' customer Valneva in the development of the vaccine. Find out how Albumin solved the challenge.

Read Now

Recombumin® Applications

  • Cell Therapies
  • Gene Therapies
  • Viral Based Therapies
  • Protein Based Therapies
  • Media Applications
  • Medical Device Applications

View ProductsDownload Data Sheet

Services and Solutions for Recombinant Albumin

Not sure how to fully maximize the benefits of albumin to optimize performance, quality or consistency in your application? Our technical experts can increase your likelihood of technical and commercial success.

  • Species Specific Albumin
  • Formulation Development
  • Process Optimization
  • Bespoke Product Manufacture

Find out More

Are you losing time navigating complex quality, technical or regulatory challenges? Sartorius is on hand with a range of bespoke compliance services, designed to empower success in your development. We'll get you to the market quickly and safely.

  • Regulatory Support
  • Quality and Analytical Services
  • Characterization Services

Find out More

Sartorius’ drug delivery technology platform, Veltis®, uses engineered recombinant albumin to enhance albumin’s intrinsic characteristics for optimal therapeutic performance of your API.

  • Extend drug half life
  • Tissue Specific targeting
  • Bispecific delivery

Find out More

FAQs

They are manufactured at our site in Nottingham, UK from our proprietary Saccharomyces yeast strains, at ICH Q7 cGMP standards. As such it is the highest quality animal origin-free rAlb product commercially available.

Yes – As an example, Recombumin® is already used in two marketed vaccine products; Merck & Co’s MMR®-II and Proquad® childhood vaccine.

Please visit our Recombumin® product page for further product information or to submit an inquiry.

Sartorius Albumedix Limited
Mabel Street
NOTTINGHAM
NG2 3ED
UNITED KINGDOM

Sartorius offers sample-sized volumes for the Recombumin® portfolio to permit the evaluation of our recombinant human albumins in your specific application. Request sample volumes today using our eShop.

Please check out our careers page here on Sartorius.com where we list all the current opportunities that we have for you to join our team.

Complete our contact form, and one of our team members will contact you to discuss how Recombumin® could support your process. We have four decades of experience pioneering albumin-enabled solutions, and we are always keen to engage with new customers. 

icon-puzzle

Now Part of Sartorius

In recent years, Sartorius has been continuously making acquisitions, expanding its portfolio by new, complementary technologies.

Explore Recent Acquisitions

Consult Our Experts

Ready to Buy?